AI Article Synopsis
- Researchers evaluated the effectiveness of Iripallidal, a bicyclic triterpenoid, against glioblastoma multiforme (GBM) due to its resistance to traditional chemotherapy.
- The study utilized cell line tests to measure Iripallidal's impact on cancer cell growth, apoptosis, and specific signaling pathways (like Akt/mTOR and STAT3), as well as its effects on cell cycle, DNA damage, and telomerase activity.
- Results showed that Iripallidal induced cancer cell death, inhibited key signaling pathways, and was also effective against various other non-glioma cancer cell lines, suggesting potential as a new treatment for GBM.
Article Abstract
Background: The highly resistant nature of glioblastoma multiforme (GBM) to chemotherapy prompted us to evaluate the efficacy of bicyclic triterpenoid Iripallidal against GBM in vitro.
Methods: The effect of Iripallidal on proliferation and apoptosis in glioma cell lines was evaluated by MTS, colony formation and caspase-3 activity. The effect of iripallidal to regulate (i) Akt/mTOR and STAT3 signaling (ii) molecules associated with cell cycle and DNA damage was evaluated by Western blot analysis. The effect of Iripallidal on telomerase activity was also determined.
Results: Iripallidal (i) induced apoptosis, (ii) inhibited Akt/mTOR and STAT3 signaling, (iii) altered molecules associated with cell cycle and DNA damage, (iv) inhibited telomerase activity and colony forming efficiency of glioma cells. In addition, Iripallidal displayed anti-proliferative activity against non-glioma cancer cell lines of diverse origin.
Conclusion: The ability of Iripallidal to serve as a dual-inhibitor of Akt/mTOR and STAT3 signaling warrants further investigation into its role as a therapeutic strategy against GBM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2916920 | PMC |
| http://dx.doi.org/10.1186/1471-2407-10-328 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!